The Association of the British Pharmaceutical Industry
Medicines are transforming our lives like never before.
We want the UK to be the best place in the world to research, develop and use the medicines and vaccines of the future.
- Valuing and accessing medicines
- RESEARCH, DEVELOPMENT AND MANUFACTURING
- WORKING IN PARTNERSHIP
- Industry Reputation
- International Policy, Trade & IP
- Health Data
Valuing and accessing medicines
Ensuring value, access and uptake of innovative medicines and vaccines, now and in the future
Medicines bring huge value to NHS patients. The development of new medicines is uncertain, costly, and involves significant rates of failure. The pharmaceutical industry spends $160 billion per year on research and development.The private sector produces nearly all the medicines and vaccines available to us. Companies need to make a profit – and a return – on global investment in order to maintain investment in the next generation of medicines.
RESEARCH, DEVELOPMENT AND MANUFACTURING
Improving the UK's attractiveness for industry, research, development and manufacturing
We're helping to build a thriving environment for medicine discovery so the UK can be the best place in the world to research and develop new medicines and vaccines.
WORKING IN PARTNERSHIP
Building better partnerships between industry and NHS and across the Life Sciences sector
We have a long-standing positive relationship with the NHS, and a record of facilitate the same across various parties across the Life Sciences sector. We believe in focusing collaboration on where it can add the most value in making innovation as widely available to patients as possible.
Industry Reputation
Building a stronger industry reputation in the UK
Everywhere, every day someone relies on the results of our work to ensure their health and wellbeing. We are proud of this and are committed to working with a wide range of people - patients, doctors, nurses, regulators and governments - in order to deliver medicines in an ethically responsible way. Patients are at the heart of everything that we do.
International Policy, Trade & IP
Providing international leadership and driving global policy
The ABPI is working to ensure that the UK has the best relationship with our international partners for patients, public health and the life sciences sector.
Health Data
Improving the UK's health data capability and industry's access to data
We aim to harness the UK’s health data to support the efficient design, feasibility, recruitment and conduct of the full range of clinical trials. We are helping the UK make the most of health-related data for future research and development into new medicines.
Transforming lives, raising productivity
A new report from PwC for the Association of the British Pharmaceutical Industry reveals a picture of variable and slow access to the newest, innovative treatments.
Read the report from PwC on the value of medicinesLatest news
Eligible NHS patients missing out on new medicines that could extend lives and add £billions to the UK economy
New research by PwC for the ABPI published today sets out the potential benefits of increased investment in clinically- and cost-effective new medicines to patients, society, and the economy.
ABPI response to 'Healthy Mum, Healthy Baby, Healthy Future' report
The 'Healthy Mum, Healthy Baby, Healthy Future' report from the University of Birmingham sets out the case for developing more medicines for use in pregnancy.
ABPI response to meeting between industry and Government on HRT supply
The ABPI welcomed today’s meeting between industry and Government on HRT supply.
ABPI welcomes appointment of Madelaine McTernan as Head of HRT Taskforce
It's important that women who need HRT can get the medicines they need
Latest blogs and events
Working together, we are all determined to create more medicines for pregnant women
Steve Hoare, the ABPI's Head of Safety and Quality, talks about how industry is trying to address the lack of medicines approved for pregnant women.
Worth the wait – The Goldacre review
Our thoughts on Professor Ben Goldacre’s “Better, broader, safer” report into health data.
Innovative medicines can bring hope to people with rare diseases – let’s get them to patients
England’s Action Plan for Rare Diseases contains important commitments to ensure that people with rare diseases get faster diagnosis, better care and timelier access to the treatments they desperately need.
Online Workshop on SMC: How to prepare and submit to SMC | 13-14 June 2022
Making high quality, evidence-based submissions to SMC can mean the difference between successful or very limited access to NHS Scotland for medicines.
Key content hubs
We stand in solidarity with the people of Ukraine and condemn the invasion of their country. As an industry dedicated to saving lives, we stand for peace.
The COP26 summit will bring parties together to accelerate action towards the goals of the Paris Agreement and the UN Framework Convention on Climate Change.
As a critical part of the health care community in the UK, the pharmaceutical industry wants to play the biggest possible role in the response to COVID-19.
The ABPI Code of Practice sets out the requirements the industry must comply with and supports companies’ commitment to self-regulation and to operate in a professional, ethical and transparent manner.
The #COVID19 pandemic taught us hard-learned lessons that can inform how we create a healthier, safer, more equitable world.
— IFPMA (@IFPMA) May 23, 2022
10 insights from the biopharmaceutical industry from this pandemic to guide future efforts➡️https://t.co/dfikQbC4nc pic.twitter.com/2uSxFelIJP
Great to hear @annietrev launch the negotiations for a new free trade deal with Mexico. There’s real opportunity to boost life sciences exports from the U.K. if we prioritise the right policy issues. I look forward to supporting @tradegovuk 🇲🇽 🇬🇧 pic.twitter.com/wQx2knkKZ9
— Richard Torbett (@TorbettR) May 20, 2022
Happy #ClinicalTrialsDay! Our Chief Executive @TorbettR celebrated at the @RoyalFreeNHS
— ABPI (@ABPI_UK) May 20, 2022
We want to spread the research-active culture that they have, so that more people can be part of research and we discover the treatments of the future. 🔬🧬🧑🤝🧑 pic.twitter.com/pMb5yVkDqT
Many thanks to @RoyalFreeNHS for having our Chief Exec @torbettr to speak at your Bench to Bedside event today on #WorldClinicalTrialsDay22 https://t.co/tNPmxVagJX
— ABPI (@ABPI_UK) May 20, 2022
The Pharmaceutical Industry in the UK
![Turnover [1]](/media/n5lbxuf1/figures-turnover-36-7bn.jpg)
![R and D Investment [2]](/media/4dufmenf/figures-r-d-investment-4-8bn.jpg)
Members
Online members portal (ABPI Meetings via Adam.ai)
ABPI members can log in for bespoke content and services.
Transforming lives, raising productivity
Our new report from PwC revealing the picture of medicines access in the UK.